John D. Ayers
Advanced in Richter Syndrome

Dr. John D. Ayers

Hematology | Oncology
4405 Weaver Pkwy, 
Waterman, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
30 Years of Experience
Advanced in Richter Syndrome
4405 Weaver Pkwy, 
Waterman, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Ayers is a Hematologist and an Oncologist in Waterman, Illinois. Dr. Ayers has been practicing medicine for over 30 years and is rated as an Advanced provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Inflammatory Breast Cancer, and Myelodysplastic Syndrome (MDS).

His clinical research consists of participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Illinois At Chicago College Of Medicine, 1995
Residency
Boston University Medical Center
Specialties
Hematology
Oncology
Licenses
Internal Medicine in IL
Board Certifications
American Board Of Internal Medicine - Hematology (Certified)
Hospital Affiliations
Northwestern Medicine Kishwaukee Hospital
Northwestern Medicine Delnor Community Hospital
Northwestern Medicine Central Dupage Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
MetLife
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

4405 Weaver Pkwy, Waterman, IL 60555

Additional Areas of Focus

Dr. Ayers has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Melanoma
Breast Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy
A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy
Enrollment Status: Recruiting
Publish Date: September 19, 2024
Intervention Type: Device, Other
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2025
Intervention Type: Other, Procedure
Study Phase: Phase 2
Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias
Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 10, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Enrollment Status: Completed
Publish Date: June 27, 2018
View 9 Less Clinical Trials
Similar Doctors
Distinguished in Richter Syndrome
Dr. Shuo Ma
Hematology | Oncology
Distinguished in Richter Syndrome
Dr. Shuo Ma
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (29.6 miles away)
866-587-4322
Experience:
31+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shuo Ma is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Ma has been practicing medicine for over 31 years and is rated as a Distinguished provider by MediFind in the treatment of Richter Syndrome. Her top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), and Bone Marrow Aspiration.

Distinguished in Richter Syndrome
Dr. Nadia N. Khan
Hematology | Oncology | Transplant Surgery
Distinguished in Richter Syndrome
Dr. Nadia N. Khan
Hematology | Oncology | Transplant Surgery

Rush University Medical Group

1520 W Harrison St, 
Chicago, IL 
 (27.5 miles away)
312-942-5904
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nadia Khan is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Khan is rated as a Distinguished provider by MediFind in the treatment of Richter Syndrome. Her top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, and Chronic Lymphocytic Leukemia (CLL). Dr. Khan is currently accepting new patients.

Distinguished in Richter Syndrome
Dr. Parameswaren Venugopal
Hematology | Oncology
Distinguished in Richter Syndrome
Dr. Parameswaren Venugopal
Hematology | Oncology

Rush University Medical Group

1620 W Harrison St, 
Chicago, IL 
 (26.6 miles away)
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Parameswaren Venugopal is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Venugopal is rated as a Distinguished provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Venugopal is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ayers's expertise for a condition
ConditionClose
    View All 19 Advanced Conditions
    View All 45 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile